Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial

Reginster, Jean-Yves, Badurski, Janusz, Bellamy, Nicholas, Bensen, William, Chapurlat, Roland, Chevalier, Xavier, Christiansen, Claus, Genant, Harry, Navarro, Federico, Nasonov, Evgeny, Sambrook, Philip N., Spector, Timothy D. and Cooper, Cyrus (2013) Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 72 2: 179-186. doi:10.1136/annrheumdis-2012-202231


Author Reginster, Jean-Yves
Badurski, Janusz
Bellamy, Nicholas
Bensen, William
Chapurlat, Roland
Chevalier, Xavier
Christiansen, Claus
Genant, Harry
Navarro, Federico
Nasonov, Evgeny
Sambrook, Philip N.
Spector, Timothy D.
Cooper, Cyrus
Title Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
Journal name Annals of the Rheumatic Diseases   Check publisher's open access policy
ISSN 0003-4967
1468-2060
Publication date 2013-02
Year available 2012
Sub-type Article (original research)
DOI 10.1136/annrheumdis-2012-202231
Volume 72
Issue 2
Start page 179
End page 186
Total pages 8
Place of publication London, United Kingdom
Publisher B M J
Collection year 2013
Language eng
Formatted abstract
Background: Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis.

Methods: Patients with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) 2.5-5 mm) were randomly allocated to strontium ranelate 1 g/day (n=558), 2 g/day (n=566) or placebo (n=559). The primary endpoint was radiographical change in JSW (medial tibiofemoral compartment) over 3 years versus placebo. Secondary endpoints included radiological progression, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and knee pain. The trial is registered (ISRCTN41323372).

Results: The intention-to-treat population included 1371 patients. Treatment with strontium ranelate was associated with smaller degradations in JSW than placebo (1 g/day: -0.23 (SD 0.56) mm; 2 g/day: -0.27 (SD 0.63) mm; placebo: -0.37 (SD 0.59) mm); treatment-placebo differences were 0.14 (SE 0.04), 95% CI 0.05 to 0.23, p<0.001 for 1 g/day and 0.10 (SE 0.04), 95% CI 0.02 to 0.19, p=0.018 for 2 g/day. Fewer radiological progressors were observed with strontium ranelate (p<0.001 and p=0.012 for 1 and 2 g/day). There were greater reductions in total WOMAC score (p=0.045), pain subscore (p=0.028), physical function subscore (p=0.099) and knee pain (p=0.065) with strontium ranelate 2 g/day. Strontium ranelate was well tolerated.

Conclusions: Treatment with strontium ranelate 1 and 2 g/day is associated with a significant effect on structure in patients with knee osteoarthritis, and a beneficial effect on symptoms for strontium ranelate 2 g/day.
Keyword Strontium ranelate
Osteoporosis
Trial
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online first: 1 November 2012.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 97 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 120 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 10 Feb 2013, 00:15:45 EST by System User on behalf of National Research on Disability and Rehabilitation Medicine